

Retroperitoneal fibrosis

Inflammatory fibrotic process in the retroperitoneum causing compression of retroperitoneal structures, including ureters.

Incidence 1:200,000

Peak age 40-60

Males > females 2:1

Aetiology

Idiopathic (70%)

? immune response to ceroid, a polymer of oxidised lipids and protein from atherosclerotic plaques

Drugs

Methysergide* migraine treatment

LSD*

Bromocriptine*

Methyldopa*

*all ergot alkaloids

Beta blockers

Phenacetin

Amphetamine

Malignancy

Lymphoma

Sarcoma

Carcinoma of breast, colon, stomach and prostate

Infection

TB

Schistosomiasis

Chronic UTI

Syphillis

Gonorrhoea

Actinomyces

Radiation

Inflammatory

IBD

Sarcoidosis

Endometriosis

Collagen diseases

Inflammatory AAA

Multifocal fibrosclerosis

rare condition characterised by RPF mediastinal and mesenteric fibrosis sclerosing cholangitis, Reidel's thyroiditis and orbital pseudotumour

Presentation

Relatively non-specific often with delayed diagnosis

Vague back pain

Lethargy

Anorexia

Weight loss

Symptoms attributable to disease process

Ureters oliguria, weight gain, SOB

IVC DVT

Renal vein hypertension, haematuria

Pathology

Smooth, flat tan-coloured mass of tissue overlying ureters

Histology	Early phase	collagen and inflammatory cells
	Late phase	collagen
	Malignancy RPF	collagen and occasional islands of tumour cells

Diagnosis

Raised ESR, CRP, anaemia and leucocytosis common but non-specific

No current diagnostic serological test

IVU shows varying degree of obstruction with medial deviation of ureters
(NB. medial deviation seen in ~20% of normal individuals)

CT or MRI with or without contrast are the investigations of choice

Except in a few obvious cases of lymphoma, cross-sectional imaging not sufficient to exclude malignancy: Campbell's states that:

'Representative **biopsies of the mass need to be obtained** ..to rule out malignancy and allow one to proceed with treatment for RPF' However some believe that biopsy not required if:

Classic features of RPF on CT/MRI

No lymphadenopathy

No history of prior malignancy

? a role for PET scanning in this situation to exclude requirement for biopsy - both lymphoma and sarcoma positive on FDG-PET

Management

Initial management comprises decompression of urinary tracts or Mx of DVT

Primary high dose steroid therapy

Effective in ~80%

?better in those with high ESR, leucocytosis or inflammatory cells on biopsy

Duration of treatment unknown; > 6 months recommended, but because of relapse rate (?value) some advocate longer term Rx Rx schedule (Kardar 2002) in Campbell's:

(ESR). The steroids were started with an initial oral intake of 60 mg. prednisolone on alternate days for 2 months. This dose was tapered during the next 2 months (40 mg. for 2 weeks, 20 mg. for 2 weeks and 10 mg. for 2 weeks) to a maintenance dose of 5 mg. daily. Total duration of steroid use was 2 years.

Steroid-sparing immunosuppressants including azathioprine, cyclosporine, mycophenylate mofetil and tamoxifen all reported to have efficacy. Possible role for non-steroid immunosuppressants in preventing relapse after short-course of high-dose steroids (Swartz RD 2009)

Surgical management for non-responders:

Open ureterolysis

Midline incision

Medial mobilisation of left and right colon

Initial biopsy +/- frozen section

Right-angle from normal ureter to abnormal

Placement of ureters in peritoneum or omental wrap

If inadvertent uretotomy leave stents longer post-op

Laparoscopic ureterolyis

First report Clayman and Kavoussi 1992

Data on 13 patients reported in 2002

All pre-stented and placed in peritoneum by tacking white line

back to original site *underneath* ureter

Conversion in 15% for bleeding/failure to progress; no

intrabdominal complications; 92% unobstructed at 30 months